Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb 1;137(2):377-378.
doi: 10.1097/AOG.0000000000004270.

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

Sarah N Bernstein, Alyssa M Peckham  1 , Davida M Schiff, Jessica R Gray  2
Affiliations
Comment

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

Sarah N Bernstein et al. Obstet Gynecol. .
No abstract available

PubMed Disclaimer

Comment in

  • In Reply.
    Cleary EM, Kate Byron R, Hinely KA, Talley AW, Costantine MM, Rood KM. Cleary EM, et al. Obstet Gynecol. 2021 Feb 1;137(2):378. doi: 10.1097/AOG.0000000000004269. Obstet Gynecol. 2021. PMID: 33481517 No abstract available.

Comment on

References

    1. Cleary EM, Byron RK, Hinely KA, Talley AW, Costantine MM, Rood KM. Subcutaneous buprenorphine extended-release use among pregnant and postpartum women. Obstet Gynecol 2020;136:902–3. doi: 10.1097/AOG.0000000000004126 - DOI
    1. Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med 2019;13:93–103. doi: 10.1097/ADM.0000000000000457 - DOI
    1. Winhusen T, Lofwall M, Jones HE, Wilder C, Lindblad R, Schiff DM, et al. Medication treatment for opioid use disorder in expectant mothers (MOMs): design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemp Clin Trials 2020;93:106014. doi:10.1016/j.cct.2020.106014 - DOI

LinkOut - more resources